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Purpose: Many studies have revealed that diabetes mellitus (DM) increases a person’s lifetime risk of colorectal cancer and 
that DM is associated with a worse outcome of colon cancer, but this association is controversial. In this study, we in-
tended to examine the relationship between DM and the long-term outcomes of colorectal cancer.
Methods: A retrospective analysis was conducted on 657 patients who underwent surgery due to colorectal cancer be-
tween 1997 and 2004 at Korea Cancer Center Hospital. The operations were done by a single surgeon. With a median fol-
low-up of 4.7 years, we analyzed differences in recurrence-free survival (RFS) and overall survival (OS) between patients 
with DM and those without DM.
Results: Of the 657 patients, 374 (57%) were males and 67 (10%) had DM. There was no difference in age at diagnosis, sex 
and pathologic stage of colorectal cancer according to the presence of DM. There were no difference in the RFS and the 
OS of colon cancer between the patients with DM and those without DM. At 5 years, the RFS was 71.3% in diabetic pa-
tients vs. 70.4% in non-diabetic patients (P = 0.480), and the OS was 68.8% in diabetic patients vs. 75.0% in non-diabetic 
patients (P = 0.498). There was no difference in the median survival between the groups (9.6 years in the diabetic group 
vs. 10.6 years in the non-diabetic group; P = 0.495).
Conclusion: In this study, we did not find any relation between the presence of DM and either the recurrence or the sur-
vival in cases of colorectal cancer. More studies to elucidate whether the influence of DM is directly related to a higher 
rate of cancer recurrence or survival are needed.
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Many studies have reported that type 2 DM is related to the 
risk of developing cancer. Many studies of meta analysis revealed 
that a history of DM significantly increased the incidence of 
liver, pancreatic, colorectal, renal, bladder, endometrial, and 
breast cancer [4-10]. A ten-year prospective cohort study of 
1,298,385 Koreans who received health insurance from the 
National Health Insurance Corporation showed elevated fast-
ing serum glucose levels and a diagnosis of DM to be indepen-
dent risk factors for several major cancers, and the risk tended 
to increase with increasing level of fasting serum glucose [11].
The association between DM and colorectal cancer has been 
studied most actively. Many reports demonstrated that the risk 
of colorectal cancer was increased in DM patients [6, 12]. In ad-
dition, DM affected the prognosis for colorectal cancer. Cough-
lin et al. [13] reported that the mortality rate for colorectal can-
cer was higher in patients with DM, and a study by Meyerhardt 
et al. [14] reported that the five-year survival rate for colorectal 
INTRODUCTION 
The prevalence of diabetes mellitus (DM) is rapidly increasing 
worldwide. During the last 30 years in Korea, the prevalence 
of DM has become 5-6 times higher increasing from 1.5% to 
approximately 10% [1-3].This increase is much higher than 
that of other developed countries such as the US.
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cancer was reduced in DM patients. 
As the prevalence of DM increases, the prevalence of colorec-
tal cancer with DM will increase. If DM were to be found to 
affect the prognosis for colorectal cancer, it would be a serious 
health issue. To determine the effect of DM on the outcomes 
for colorectal cancer, we conducted a retrospective analysis of 
colorectal cancer patients who underwent surgery. 
METHODS
This study analyzed retrospectively the data on 657 colorectal 
cancer patients who underwent surgery by a single surgeon at 
Korea Cancer Center Hospital from 1997 to 2004. All patients 
had a histologically confirmed adenocarcinoma, and the mean 
follow-up duration was 4.7 years. Based on the medical records, 
the existence of DM, age at diagnosis of colorectal cancer, gen-
der, stage at diagnosis, histological differentiation, recurrence, 
and survival were examined. Patients that either had a history 
of DM or were taking medications for DM were classified as 
DM patients. 
The survival rate and the recurrence rate were analyzed ac-
cording to the existence of DM. Overall survival (OS) was de-
fined as the time from study entry to death from any cause. 
Recurrence-free survival (RFS) was defined as the time from 
study entry to tumor recurrence or occurrence of a new pri-
mary colon cancer. For RFS, patients who died without known 
recurrence were selected at their final documented evaluation.
Statistical analysis was conducted with SPSS ver.12.0 (SPSS 
Inc., Chicago, IL, USA), and a P-value of less than 0.05 was 
considered to be statistically significant. The distribution of 
baseline characteristics between DM and non-DM patients 
was evaluated using either Fisher’s exact or χ2 tests in the case 
of categorical variables or student’s t-test in the case of contin-
uous variables. The OS and the RFS were examined using the 
Kaplan-Meier method and a Cox proportional hazards regres-
sion analysis.
RESULTS
Of the 657 patients included in our analysis, 67 (10%) had DM. 
The clinical characteristics of the subjects according to DM are 
presented in Table 1. The mean age of the DM group was higher 
than that of non-DM group (61.2 ± 11.2 years and 57.6 ± 10.3 
years, respectively). Among the subjects, 374 (57%) were male, 
and 283 were female (43%), and there was no significant differ-
ence in gender according to DM. The body mass index (BMI) 
was significantly higher in the DM group than in the non-DM 
group (24.9 ± 3.7 kg/m
2 and 23.2 ± 3.1 kg/m
2, respectively). In 
addition, for the patients with a BMI of over 25 kg/m
2, the prev-
alence of DM was 16.9%, which was significantly higher than 
the 7.1% for those with a BMI of less than 25 kg/m
2 (P < 0.001). 
The stage at diagnosis of colorectal cancer and the histological 
differentiation of colorectal cancer were not different between 
the DM and the non-DM groups.
The survival rate and the recurrence rate were analyzed ac-
cording to presence or absence of DM. Kaplan-Meier curves 
presenting the OS and the RFS are shown in Figs. 1, 2, respec-
Table 1. Baseline characteristics for 657 patients with colorectal cancer
Variable
No DM  
(n = 590)
DM  
(n = 67)
P-value
Age    57.6 ± 10.3   61.2 ± 11.2 0.010
Gender (M:F) 332:258 42:25 0.303
BMI (kg/m
2)  23.2 ± 3.1 24.9 ± 3.7 0.001
T stage (depth)
   T1
   T2
   T3
   T4
   28 (5.3)
  79 (15)
   284 (53.9)
   136 (25.8)
    2 (3.4)
      6 (10.3)
    39 (67.2)
    11 (19.0)
0.285
N stage (positive LN)
   N0 (0 node)
   N1 (1-3 nodes)
   N2 (> 4 nodes)
   306 (58.1)
   140 (26.6)
     81 (15.4)
    36 (62.1)
    15 (25.9)
      7 (12.1)
0.767
Stage
   I
   II
   III
   IV
     85 (14.4)
   250 (42.4)
   220 (37.3)
   35 (5.9)
      7 (10.4)
    32 (47.8)
    26 (38.8)
    2 (3.0)
0.563
Grade
   Well
   Moderate
   Poor
   Other
183 (31)
   371 (62.9)
   23 (3.9)
   13 (2.2)
    19 (28.4)
    44 (65.7)
    4 (6.0)
 0 (0)
0.678
Values are presented as mean ± SD or number (%). 
DM, diabetes mellitus; BMI, body mass index; LN, lymph node.
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Fig. 1. Overall survival for patients with colorectal cancer by diabe-
tes mellitus (DM) status.
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tively. The five-year survival rate in the DM group was 68.0% 
and that in the non-DM group was 75%, the difference not be-
ing statistically significant (P = 0.498). The five-year RFS rate 
in the DM group was 64.0% and that in the non-DM group was 
69.0%, the difference not being statistically significant (P = 0.954). 
In the Cox proportional hazard regression analysis, we exam-
ined the influence of DM after adjustment for age and BMI. In 
the non-DM group, in comparison to the DM group, the risk 
of recurrence was lower by 6.2%, and death was lower by 25%, 
but the difference was not significant (Table 2). Moreover, when 
we compared the mean survival of the DM and the non-DM 
groups, they were not significantly different (9.6 years and 10.6 
years, respectively, P = 0.495).
DISCUSSION
This study showed that the recurrence rate and the survival rate 
for colorectal cancer after surgery were not significantly differ-
ent according to the presence or absence of DM. In addition, 
we could not find any significant correlation between DM and 
the occurrence of colorectal cancer when we consider that the 
prevalence of DM among the colorectal cancer patients in this 
study was almost the same prevalence as in the general Korean 
population during the same period [1-3]. Many studies reported 
an increased risk of DM patients developing colorectal cancer. 
The suggested mechanisms were hyperinsulinemia caused by 
insulin resistance, increase of insulin-like growth factor (IGF), 
changes of adipocytokines, chronic inflammation and increased 
oxidative stress in DM patients.
IGF-1 is an important hormone for growth and development, 
and leads to cell division and cell transformation. IGF binding 
protein (IGFBP) inhibits its roles by binding with IGF. In hy-
perinsulinemia, insulin is known to bind directly to the IGF-1 
receptor or to work in competition with IGFBP to increase the 
free IGF-1 level in the blood and eventually to be able to in-
duce cancer by inhibiting apoptosis and promoting cell prolif-
eration [15, 16]. In addition, slower bowel transit time and ele-
vated fecal bile acid concentrations frequently observed in DM 
allow more exposure to toxic materials, thus p provoke colorec-
tal cancer [17]. Moreover, when the blood sugar level is not 
well-controlled, oxidative stress is increased, and this leads to 
a pro-inflammatory condition. Reactive oxygen species (ROS) 
are known to damage cellular DNA and to promote cancer in 
various steps by reacting with proteins or lipids in cells [18].
There are several reports that the prognosis for colorectal can-
cer is poor in DM patients. In a study conducted with 3,759 
surgically treated colorectal cancer patients, the five-year dis-
ease-free survival and OS rates were significantly decreased, 
even after adjustments for age, gender, race, and stage, location 
and histological differentiation of tumors [14]. Meta analyses 
on the mortality rate, recurrence rate and treatment-related 
complications of colorectal cancer [19] revealed that peri-op-
erative short-term mortality rates were higher among DM pa-
tients; the long-term mortality rate was also increased by 32% 
in DM patients. Limited use of anticancer drugs because of com-
plications of DM, such as cardiovascular disease and renal and 
nervous disease, and higher risk of infection after anti-cancer 
therapy could explain the high mortality rate in DM patients. 
However, when we consider Meyerhardt et al. [14] report that 
the recurrence rate of cancer was also higher in DM patients, 
we should also consider that the increased recurrence caused 
by DM may have led to the increased mortality.
However, other studies did not find any correlation between 
DM and the incidence of or the prognosis for colorectal cancer. 
An epidemiological study of Kune et al. [20] reported that the 
prevalence of DM in colorectal cancer patients was the same 
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Fig. 2. Recurrence-free survival for patients with colorectal cancer 
by diabetes mellitus (DM) status.
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Table 2. Hazard ratio of diabetes in colorectal cancer 
Recurrence Overall survival
No. of recurrences HR (95% CI) No. of deaths HR (95% CI)
No DM (n = 590) 192 0.938 (0.795-1.131) 155 0.751 (0.585-1.031)
DM (n = 67)    21 1.0   19 1.0
P-value 0.786 0.247
HR, hazard ratio; CI, confidence interval; DM, diabetes mellitus. Journal of The Korean Society of
Coloproctology
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as that of the control group. Another epidemiological study by 
Will et al. [21], which included 1 million persons, reported that 
the risk of colorectal cancer was higher in DM patients, but there 
was no difference in mortality rate according to DM. In addi-
tion, a study by Shonka et al. [22] did not show any significant 
correlation between DM and the prognosis for colorectal cancer. 
Also, our study did not observe any correlation between colorec-
tal cancer and DM. One reason that the correlation between 
DM and colorectal cancer is different may be various DM-re-
lated factors, such as obesity, therapeutic agents and blood sugar 
control, not having been controlled properly. Second reason 
may be due to the different criteria used in each study to de-
fine the existence of DM. As most studies defined the existence 
of DM according to reports of patients instead of applying glu-
cose tolerance test, there could be DM patients who were not 
classified as DM patients. Another reason may be hyperinsu-
linemia due to insulin resistance being maintained only in the 
early stage of DM. With the progress of DM, hypoinsulinae-
mia is observed because of islet-cell dysfunction. The negative 
effect of hyperinsulinemia on the prognosis for colorectal can-
cer could diminish. 
As limitations of this study, the number of subjects is relatively 
small, and the analysis was retrospective. Moreover, because 
we defined the existence of DM only as a medical history DM 
or a history of medications for DM in the medical record, some 
actual DM patients might not have been included in the DM 
group. However, this study has a strong point in that the sub-
jects underwent surgery by a single surgeon at a single center 
so that the difference in complications and prognosis caused 
by the difference in surgical techniques could be excluded. 
Considering that the prevalence of DM has increased greatly, 
many DM patients are not diagnosed, and the risk of cancer 
increases due to longer life expectancy, the increase in the oc-
currence of and the mortality from colorectal cancer in DM 
patients is expected to become a very important issue of public 
health. More large-scaled prospective studies are necessary in 
the future, and more efforts to use exact diagnostic criteria of 
DM in a study are needed. In addition, investigating the prog-
nosis of colorectal cancer according to blood sugar control is 
thought to be clinically important, and measuring the blood 
insulin levels of the subjects may be helpful in elucidating the 
mechanism of colorectal cancer development in DM patients. 
This study to investigate the effect of DM on the prognosis for 
colorectal cancer did not show any differences in the stage at 
diagnosis, the survival rate and the recurrence rate of colorec-
tal cancer according to the existence or the absence of DM. More 
large-scaled studies are necessary in the future.
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